Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733035 | 0.96 | MAPT (0.54) | GRM2CYP3A4MAPTTP53NAMPT | |
| SCHEMBL6739041 | 0.95 | CYP3A4 (0.50) | GRM2CYP3A4MAPTTP53NAMPT | |
| SCHEMBL6735083 | 0.93 | GRM2 (0.50) | GRM2CYP3A4MAPTTP53 | |
| SCHEMBL6730973 | 0.92 | MAPT (0.51) | GRM2CYP3A4MAPTTP53 | |
| SCHEMBL7419432 | 0.91 | CYP3A4 (0.49) | GRM2CYP3A4MAPTTP53GAA | |
| SCHEMBL6730763 | 0.90 | CYP3A4 (0.59) | GRM2CYP3A4MAPTTP53GAA | |
| SCHEMBL6727717 | 0.88 | CYP19A1 (0.48) | GRM2CYP3A4MAPTTP53 | |
| SCHEMBL6739403 | 0.87 | MAPT (0.51) | CYP3A4MAPTTP53 | |
| SCHEMBL6739591 | 0.87 | CYP3A4 (0.46) | GRM2CYP3A4MAPTTP53NAMPT | |
| SCHEMBL6732626 | 0.87 | GRM2 (0.55) | GRM2CYP3A4MAPTTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885CYP3A4 2786/4885MAPT 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.